James Bullard said he dissented on this week's Fed decision to lower rates by a quarter percentage point because he didn't think the cut was big enough.The Fedread more
More than 400 Chinese products will be temporarily exempted from tariffs that President Donald Trump's administration imposed last year.China Economyread more
"I feel like I've contributed all I can to this primary election," he told MSNBC's "Morning Joe." "And it's clearly not my time. So I'm going to end my presidential campaign."2020 Electionsread more
Apple will get a taste of whether upgraded features on the new iPhone 11 are enough to lure shoppers to retail stores around the world as the new smartphones officially hit...Technologyread more
The complaint made by an unnamed intelligence official about the president centers on Ukraine, the Washington post reported.Politicsread more
Apple CEO Tim Cook greeted iPhone 11 customers at the reopening of the Fifth Avenue Apple store on Friday. CNBC also took a tour inside. Here's a look.Technologyread more
The Pentagon on Thursday said the recent attack on Saudi Arabian oil facilities were "sophisticated" and represented a "dramatic escalation" in tensions within the region.Defenseread more
Joshua Harris, Apollo Global Management's co-founder, has a message for private equity's naysayers in Washington.Delivering Alpharead more
Bank of America says Amazon's plans to build its own fleet of carbon-neutral delivery trucks bode well for its bottom line.Investingread more
The show comes as social media platforms and legacy media companies alike have launched a flurry of original content alongside new streaming platforms like Apple TV+ and...Technologyread more
Pivotal Research Group began coverage of Roku with a sell rating on FridayInvestingread more
Pharmaceutical giant Pfizer braced investors for little-to-no revenue growth in 2019 after its blockbuster erectile dysfunction drug Viagra, among others, lost patent protection and pain killer Lyrica faces similar competition from generic drugmakers this year.
Shares of Pfizer fell 2.7 percent in premarket trading Tuesday even after the drugmaker announced fourth-quarter earnings that exceeded Wall Street predictions. However, the stock was up more than 1 percent by midmorning trading amid the post-earnings conference call.
Here's how the company did compared with what Wall Street expected:
Pfizer's adjusted earnings of 64 cents per share for the quarter was 1 cent above Wall Street estimates and 2 cents higher than a year earlier. Revenue came in at $13.97 billion, higher than the projected $13.89 billion and the $13.7 billion it reported a year earlier.
Pfizer forecast its 2019 adjusted earnings to range between $2.82 to $2.92 a share, below average analysts' estimates of $3.04 a share. It sees revenue for 2019 at $52 billion to $54 billion, shy of estimates of $54.25 billion.
For the full year, Pfizer reported adjusted earnings $3 per share on revenue of $53.6 billion. It anticipates repurchasing about $9 billion of shares in 2019.
"We enter 2019 with confidence in the competitive positioning of our businesses, the prospects for our recently launched products and product line extensions, as well as the strength and breadth of our research pipeline," Pfizer CEO Albert Bourla said in a press release.
The earnings report marks Bourla's first since becoming CEO on Jan.1, succeeding Ian Read. The company announced plans to shuffle the company's senior management team in October and has been trying to bulk up its pipeline of drugs and therapies, especially in oncology, ahead of impending patent expirations.
Shares of Pfizer improved Tuesday after the company discussed on an earnings call its cancer drug portfolio and success with biosimilars.
Innovative health sales increased 8 percent, boosted by sales of blood thinner Eliquis and rheumatoid arthritis treatment Xeljanz. Sales in its essential health unit, which includes Viagra, fell 7 percent due in part to "pricing challenges" in the U.S. and generic competition, the company said. Viagra sales fell as Pfizer's blockbuster erectile dysfunction drug lost patent protection.
Pfizer's blockbuster drug Lyrica, which is expected to face generic competition later this year, brought in sales of $1.32 billion.
Shares of Pfizer have fallen more than 9 percent this year. The stock price has risen more than 1 percent during the past 12 months.